Life science teams use mama health to turn proprietary patient data into structured insights — designed to inform every commercial decision.
Three teams, one source of patient truth. Whether you're sizing a launch, briefing the medical leads, or sharpening a campaign — every team works from the same primary data, structured for their specific decision.
Legacy data lags by 3–6 months — missing the critical window for course correction. Get real-time territory analysis, switching triggers, and patient pathways drawn from primary signal.
See how Commercial uses mama healthRWE pipelines tell you what was prescribed and billed. They don't tell you why patients stopped, or what they wished their physician had asked. Mama health structures all of it — ready for evidence dossiers and advisory boards.
See how Medical Affairs uses mama healthBrand teams test concepts on synthetic audiences and HCP panels — and find out months later that patients heard something different. Close the loop in days. Ranked benchmarks against real cohorts.
See how Marketing uses mama health"The depth of patient signal we get in two weeks would take us a quarter to assemble through traditional research."
"It's the first patient intelligence tool that gives commercial and medical teams a shared evidence base."
"We argue less and decide faster — that's the change."
From kickoff to first deliverable
Stories, perspectives, and methods from life science teams using mama health to change how they launch, position, and decide.
How a Global Strategy Lead at Novartis used patient signal to surface a critical psoriasis misdiagnosis pattern — months before traditional RWE pipelines could see it.
Mama Health is a companion app used every day by people living with chronic and rare conditions — to make sense of a diagnosis, prepare for appointments, and feel less alone between visits. The depth of insight life science teams receive is a direct result of that trust.
See the patient experienceLive patient communities across chronic and rare diseases. Pulmonary Fibrosis is our current primary focus.